UNITED THERAPEUTICS Corp: settles with Liquidia for $330,400,000

What happened

• The filing says UNITED THERAPEUTICS Corp entered into a Settlement Agreement with Liquidia Technologies, Inc. on Oct 13, 2026 to resolve pending litigation between the parties.
• Under the Settlement Agreement, Liquidia will pay UT an aggregate of $330,400,000: $185,000,000 to be paid within 30 business days of the Settlement Agreement and $145,400,000 payable in two equal installments of $72,700,000 on or before Feb 1, 2027 and Apr 30, 2027. The parties agreed to seek dismissal with prejudice of the covered actions within ten days after UT receives the $185,000,000 payment, except UT may continue to pursue trade secrets claims against Dr. Robert Roscigno.
• The filing says Liquidia will immediately file an amendment with the FDA to remove the PH-ILD indication from Yutrepia’s labeling, will cease PH-ILD marketing and promotion immediately, and must cease all sales of Yutrepia bearing the PH-ILD indication upon FDA approval of the label amendment.

Key details

• Payment terms: $185,000,000 upfront within 30 business days, plus two installments of $72,700,000 on or before Feb 1, 2027 and Apr 30, 2027 (total $330,400,000).
• Patent and litigation claims named in the filing include UT’s U.S. Patent No. 11,826,327 (the ’327 patent, expires Feb 3, 2042) and U.S. Patent No. 11,357,782 (the ’782 patent, expires May 14, 2027), and Liquidia’s U.S. Patent No. 10,898,494 (the ’494 patent, expires May 5, 2037).
• Marketing and operational restrictions for Liquidia: immediate cessation of PH-ILD marketing, mandatory Group 1 PAH certification on referral/prescription forms, letters to prescribers and payers, and termination or suspension of PH-ILD cohorts in the ASCENT trial until certain patent-related dates.
• As part of the Settlement Agreement, UT agreed to pay Liquidia $10,000,000 within 30 business days to address claims in separate litigation involving RareGen/Liquidia PAH, LLC and Sandoz; the filing notes a Third Circuit decision on Oct 7, 2026 that affirmed and reversed different parts of earlier district court rulings and remanded certain claims.

Why it may matter

• This is Item 8.01, “Other events,” and the filing reports an update on litigation and a Settlement Agreement that sets payment amounts and schedule, label-change obligations for Yutrepia, dismissal and release provisions for covered proceedings, and reciprocal covenants not to sue and patent-challenge obligations. The filing does not show why the company acted.